- Home
- NVS vs AZN Comparison
NVS vs AZN Comparison
Compare NVS & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVS | AZN |
|---|---|---|
| Founded | 1895 | 1992 |
| Country | Switzerland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.3B | 283.9B |
| IPO Year | 1991 | 1993 |
Fundamental Metrics
Financial Performance| Metric | NVS | AZN |
|---|---|---|
| Price | $151.84 | $95.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $118.00 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 8.7M |
| Earning Date | 02-04-2026 | 02-10-2026 |
| Dividend Yield | ★ 1.71% | 1.61% |
| EPS Growth | N/A | ★ 45.02 |
| EPS | ★ 7.30 | 6.02 |
| Revenue | $56,372,000,000.00 | ★ $58,127,000,000.00 |
| Revenue This Year | $9.38 | $11.40 |
| Revenue Next Year | $2.69 | $6.06 |
| P/E Ratio | $20.85 | ★ $15.88 |
| Revenue Growth | 12.88 | ★ 13.52 |
| 52 Week Low | $97.72 | $61.24 |
| 52 Week High | $152.48 | $96.51 |
Technical Indicators
Market Signals| Indicator | NVS | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 77.61 | 59.67 |
| Support Level | $142.82 | $89.04 |
| Resistance Level | $146.35 | $96.43 |
| Average True Range (ATR) | 2.14 | 1.72 |
| MACD | 0.55 | -0.05 |
| Stochastic Oscillator | 95.73 | 89.16 |
Price Performance
Historical ComparisonAbout NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.